Mode of action and clinical impact of VEGF signaling inhibitors

References

• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature407, 249–257 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol.29, 10–14 (2002).
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell79, 185–188 (1994).
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol.29, 15–18 (2002).
   PubMed Web of Science ®Google Scholar
• Ribatti D, Nico B, Crivellato E et al. The history of the angiogenic switch concept. Leukemia21, 44–52 (2007).
   PubMed Web of Science ®Google Scholar
• Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother. Pharmacol.60, 151–170 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev.18, 4–25 (1997).
   PubMed Web of Science ®Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer8, 579–591 (2008).
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol.20, 4368–4380 (2002).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23, 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci.114, 853–865 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev.25, 581–611 (2004).
   PubMed Web of Science ®Google Scholar
• Nilsson M, Heymach JV. Vascular endothelial growth factor (VEGF) pathway. J. Thorac. Oncol.1, 768–770 (2006).
   PubMed Web of Science ®Google Scholar
• Veeravagu A, Hsu AR, Cai W et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Patents Anticancer Drug Discov.2, 59–71 (2007).
   PubMed Web of Science ®Google Scholar
• Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res.12, 5018–5022 (2006).
   PubMed Web of Science ®Google Scholar
• Waltenberger J, Claesson-Welsh L, Siegbahn A et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem.269, 26988–26995 (1994).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov.3, 391–400 (2004).
   PubMed Web of Science ®Google Scholar
• Hiratsuka S, Minowa O, Kuno J et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl Acad. Sci. USA95, 9349–9354 (1998).
   PubMed Web of Science ®Google Scholar
• Paavonen K, Puolakkainen P, Jussila L et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol.156, 1499–1504 (2000).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature380, 435–439 (1996).
   PubMed Web of Science ®Google Scholar
• Olsson AK, Dimberg A, Kreuger J et al. VEGF receptor signalling – in control of vascular function. Nat. Rev. Mol. Cell Biol.7, 359–371 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JC, Chow NH, Wang ST et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer.36, 748–753 (2000).
   PubMed Web of Science ®Google Scholar
• Berns EM, Klijn JG, Look MP et al. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin. Cancer Res.9, 1253–1258 (2003).
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res.7, 1932–1936 (2001).
   PubMed Web of Science ®Google Scholar
• Fontanini G, Lucchi M, Vignati S et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl Cancer Inst.89, 881–886 (1997).
   PubMed Web of Science ®Google Scholar
• Nagy JA, Vasile E, Feng D et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med.196, 1497–1506 (2002).
   PubMed Web of Science ®Google Scholar
• Barbera-Guillem E, Nyhus JK, Wolford CC et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res.62, 7042–7049 (2002).
   PubMed Web of Science ®Google Scholar
• Asano M, Yukita A, Matsumoto T et al. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res.55, 5296–5301 (1995).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature362, 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9, 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist5(Suppl. 1), 3–10 (2000).
   PubMedGoogle Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57, 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357, 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355, 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med.10, 145–147 (2004).
   PubMed Web of Science ®Google Scholar
• Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol.24, 769–777 (2006).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol.27(8), 1227–1234 (2009).
   PubMed Web of Science ®Google Scholar
• Ton NC, Parker GJM, Jackson A et al. Phase I evaluation of CDP791, a PEGylated di-fab’ conjugate that binds vascular endothelial growth factor receptor 2. Clin. Cancer Res.13, 7113–7118 (2007).
   PubMed Web of Science ®Google Scholar
• Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin. Cancer Res.13(Suppl.), S4623–S4627 (2007).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res.64, 7099–7109 (2004).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Adnane L, Newell P et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther.7, 3129–3140 (2008).
   PubMed Web of Science ®Google Scholar
• Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer92, 1855–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res.11, 5472–5480 (2005).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol.23, 965–972 (2005).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med.356, 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359, 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Keilholz U, Hogg D et al. Randomized Phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J. Clin. Oncol.25 (2007) (Abstract 8510).
   PubMed Web of Science ®Google Scholar
• Goodman VL, Rock EP, Dagher R et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res.13, 1367–1373 (2007).
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X et al.In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res.9, 327–337 (2003).
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol.24, 25–35 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368, 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Chen LL, Sabripour M, Andtbacka RH et al. Imatinib resistance in gastrointestinal stromal tumors. Curr. Oncol. Rep.7, 293–299 (2005).
   PubMedGoogle Scholar
• Demetri GD, van Oosterom AT, Blackstein M et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J. Clin. Oncol.23(16 Suppl.) (2005) (Abstract 400).
   Google Scholar
• Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res.65, 4389–4400 (2005).
   PubMed Web of Science ®Google Scholar
• Smith NR, James NH, Oakley I et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol. Cancer Ther.6, 2198–2208 (2007).
   PubMed Web of Science ®Google Scholar
• Padera TP, Kuo AH, Hoshida T et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther.7, 2272–2279 (2008).
   PubMed Web of Science ®Google Scholar
• Tammela T, Zarkada G, Wallgard E et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature454, 656–660 (2008).
   PubMed Web of Science ®Google Scholar
• He Y, Kozaki K, Karpanen T et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl Cancer Inst.94, 819–825 (2002).
   PubMed Web of Science ®Google Scholar
• Su JL, Yang PC, Shih JY et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell9, 209–223 (2006).
   PubMed Web of Science ®Google Scholar
• Heckman CA, Holopainen T, Wirzenius M et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res.68, 4754–4762 (2008).
   PubMed Web of Science ®Google Scholar
• Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.25, 3045–3054 (2007).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Laurie SA, Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol.26, 1871–1878 (2008).
   PubMed Web of Science ®Google Scholar
• Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J. Thorac. Oncol.3(Suppl.), S131–S134 (2008).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Wong RP, D’haens G et al. A Phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results. J. Clin. Oncol.26(Suppl. 12), 4028 (2008).
   Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Sridhar SS, Mackenzie MJ, Hotte SJ et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A Phase II trial of the PMH Consortium. J. Clin. Oncol.26 (20 Suppl.) (2008) (Abstract 5047).
   Google Scholar
• Gardner K, Leahy M, Alvarez-Guttierez M, Judson I, Scurr M. Activity of the VEGFR/KIT tyrosine kinase inhibitor cediranib (AZD2171) in alveolar soft part sarcoma. Presented at: Connective Tissue Oncology Society 14th Annual Meeting. London, UK, 13–15 November 2008.
   Google Scholar
• Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res.62, 7284–7290 (2002).
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res.62, 4645–4655 (2002).
   PubMed Web of Science ®Google Scholar
• Wu W, Isobe T, Itasaka S et al. ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. Proc. Am. Assoc. Cancer Res.45, 1051 (2004).
   Google Scholar
• Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol.16, 1391–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced NSCLC: results from a two-part, double-blind, randomized Phase II study. J. Clin. Oncol. (2009) (Epub ahead of print).
   Google Scholar
• Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J. Clin. Oncol.25, 4270–4277 (2007).
   PubMed Web of Science ®Google Scholar
• Heymach JV, Paz-Ares L, de Braud F et al. Randomized Phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol.26, 5407–5415 (2008).
   PubMed Web of Science ®Google Scholar
• Haddad RI, Krebs AD, Vasselli J et al. A Phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol.26(15 Suppl.), (2008) (Abstract 6024).
   Google Scholar
• Heymach JV, Paz-Ares L, De BF et al. Randomized Phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol.26(33), 5407–5415 (2008).
   PubMed Web of Science ®Google Scholar
• Wells SA, Gosnell JE, Gagel RF et al. Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label Phase II trial. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract 6018).
   Google Scholar
• Cohen EE, Rosen LS, Vokes EE et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J. Clin. Oncol.26, 4708–4713 (2008).
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res.14, 7272–7283 (2008).
   PubMed Web of Science ®Google Scholar
• Wilmes LJ, Pallavicini MG, Fleming LM et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn. Reson. Imaging25, 319–327 (2007).
   PubMed Web of Science ®Google Scholar
• George DJ. Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. Clin. Cancer Res.13, 753S–757S (2007).
   PubMed Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol.8, 975–984 (2007).
   PubMed Web of Science ®Google Scholar
• Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest.111, 1287–1295 (2003).
   PubMed Web of Science ®Google Scholar
• Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised Phase II study. Lancet371, 2101–2108 (2008).
   PubMed Web of Science ®Google Scholar
• Polverino A, Coxon A, Starnes C et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res.66, 8715–8721 (2006).
   PubMed Web of Science ®Google Scholar
• Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.25, 2369–2376 (2007).
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz JP et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med.359, 31–42 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther.6, 2012–2021 (2007).
   PubMed Web of Science ®Google Scholar
• Salgia R, Sherman S, Hong D et al. A Phase I study of XL184, a RET, VEGFR2 and MET kinase inhibitor in patients with advanced malignancies, including patients with medullary thyroid cancer. J. Clin. Oncol.26(15 Suppl.), (2008) (Abstract 3522).
   PubMedGoogle Scholar
• Kurzrock R, Sherman S, Hong D et al. A Phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) Eur. J. Cancer6(Suppl. 12) (2008) (Abstract 379).
   Google Scholar
• Kerbel RS, Viloria-Petit A, Klement G et al. ‘Accidental’ anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer36, 1248–1257 (2000).
   PubMed Web of Science ®Google Scholar
• Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother. Pharmacol.61, 661–668 (2008).
   PubMed Web of Science ®Google Scholar
• Yau T, Chan P, Wong H et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology72(Suppl. 1), 67–71 (2007).
   PubMedGoogle Scholar
• Li X, Liu X, Wang J et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res.23, 2481–2487 (2003).
   PubMed Web of Science ®Google Scholar
• Raig ET, Jones NB, Varker KA et al. VEGF secretion is inhibited by interferon-a in several melanoma cell lines. J. Interferon Cytokine Res.28, 553–561 (2008).
   PubMedGoogle Scholar
• Del VM, Bajetta E, Canova S et al. Interleukin-12: biological properties and clinical application. Clin. Cancer Res.13, 4677–4685 (2007).
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med.285, 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Liu W, Davis DW et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer89, 488–499 (2000).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307, 58–62 (2005).
   PubMed Web of Science ®Google Scholar
• Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol.21(21), 3955–3964 (2003).
   PubMed Web of Science ®Google Scholar
• Hahn OM, Yang C, Medved M et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J. Clin. Oncol.26(28), 4572–4578 (2008).
   PubMed Web of Science ®Google Scholar
• Dallas NA, Fan F, Gray MJ et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. Cancer Metastasis Rev.26, 433–441 (2007).
   PubMed Web of Science ®Google Scholar
• Bachelder RE, Crago A, Chung J et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res.61, 5736–5740 (2001).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med.7, 987–989 (2001).
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kraling BM et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res.60, 1878–1886 (2000).
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer8, 592–603 (2008).
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Bourdon MA, Hillan KJ et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate35, 1–10 (1998).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol.41, 497–504 (1998).
   PubMed Web of Science ®Google Scholar
• Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res.52, 6702–6704 (1992).
   PubMed Web of Science ®Google Scholar
• Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol.19, 1195–1206 (2001).
   PubMed Web of Science ®Google Scholar
• Gustafson DL, Merz AL, Zirrolli JA et al. Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts. Eur. J. Cancer Suppl. 2, 45 (2004).
   Google Scholar
• Siemann D, Shi W. The VEGFR2 tyrosine kinase inhibitor, ZD6474, enhances the antitumor effect of radiation. Eur. J Cancer Suppl. 2, 49 (2004).
   Google Scholar
• Williams KJ, Telfer BA, Brave S et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res.10, 8587–8593 (2004).
   PubMed Web of Science ®Google Scholar
• Kiura K, Nakagawa K, Shinkai T et al. A randomized, double-blind, Phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J. Thorac. Oncol.3, 386–393 (2008).
   PubMed Web of Science ®Google Scholar
• Kalka C, Masuda H, Takahashi T et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ. Res.86, 1198–1202 (2000).
   PubMed Web of Science ®Google Scholar
• Bertolini F, Mingrone W, Alietti A et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann. Oncol.12, 987–990 (2001).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P et al. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist12, 713–718 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.22, 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Roodhart JM, Langenberg MH, Witteveen E et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol.3, 132–143 (2008).
   PubMedGoogle Scholar
• Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis7, 193–201 (2004).
   PubMedGoogle Scholar
• Li B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension39, 1095–1100 (2002).
   PubMed Web of Science ®Google Scholar
• Heymach JV, Desai J, Manola J et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin. Cancer Res.10, 5732–5740 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hoosen S, Bello CL et al. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin. Investig. Drugs15, 553–561 (2006).
   PubMed Web of Science ®Google Scholar
• Robert C, Faivre S, Raymond E et al. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?. Ann. Intern. Med.143, 313–314 (2005).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.25(5), 740–745 (2009).
   Google Scholar